A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies Followed by an Expansion in Subjects With Measurable Disease

Inclusion Criteria:

- Voluntary written consent

- Locally advanced or metastatic solid tumors with the exception of primary brain
tumor, and have failed or are not eligible for standard of care therapy

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- Ability to swallow oral medications

- Life expectancy of ≥6 months

- For women of child-bearing potential, negative serum or urine pregnancy test within
14 days prior to the first study drug administration and use of physician-approved
method of birth control from 30 days prior to 30 days following the last study drug
administration

- Male subjects must be surgically sterile or must agree to use physician-approved
contraception during the study and for 30 days following the last study drug
administration

- Clinical laboratory values as specified in the protocol

Additionally, to be eligible for the Dose Expansion portion of the study:

- Subjects must have a pathologic diagnosis of advanced or recurrent endometrial
adenocarcinoma with histology demonstrating an endometrioid component, and must have
failed at least 1 prior line of standard chemotherapy

- Subjects must have a pathologic diagnosis of advanced/metastatic urothelial cancer
(carcinoma of the bladder, ureter, and/or renal pelvis) and must have failed at least
1 line of prior therapy in the metastatic/unresectable setting

- Subjects must have a pathologic diagnosis of advanced renal cell carcinoma (RCC),
with histological or cytological confirmation of RCC with a clear cell component, and
must have failed at least 1 prior line of anti-VEGF therapy (including but not
limited to sunitinib, and/or sorafenib, and/or bevacizumab) and must not have
received prior therapy with a TORC1 inhibitor (such as temsirolimus or everolimus);
Subjects must have progressed on VEGF-directed therapy within 6 months

- Subjects must have a pathologic diagnosis of advanced renal cell carcinoma (RCC) and
must have failed previous treatment with a TORC1 inhibitor (such as temsirolimus or
everolimus). Additional nonTORC1-directed prior therapies are allowed if subjects
have demonstrated progression on prior TORC1 inhibitor therapy within 6 months.

Exclusion Criteria:

- Diagnosis of primary brain tumor

- Have received prior cancer or other investigational therapy within 2 weeks prior to
the first administration of study drug

- Known impaired cardiac function or clinically significant cardiac disease

- Known treatment with systemic corticosteroid within one week prior to the first
administration of study drug

- Diabetes mellitus

- HIV infection

- Known active cardiovascular disease condition as specified in protocol

- Failed to recover from the reversible effects of prior anticancer therapies

- Pregnancy (positive serum or urine pregnancy test) or breast feeding

- Malabsorption due to prior gastrointestinal (GI) surgery, GI disease

- Other clinically significant co-morbidities

Please note that there are additional inclusion and exclusion criteria. The study center
will determine if you meet all of the criteria.

Site personnel will explain the trial in detail and answer any question you may have if
you do qualify for the study. You can then decide whether or not you wish to participate.
If you do not qualify for the trial, site personnel will explain the reasons